Abstract. Major causes of fasting hypoglycemia in adults are insulinoma, factitious hypoglycemia and nesidioblastosis. The primary treatment for insulinoma is surgical removal of the tumor, but there are cases with hyperinsulinemia that cannot undergo surgery. Somatostatin analogue is one of the treatments used in such cases of insulinoma or persistent hyperinsulinemic hypoglycemia. We report here a patient who had undetermined hyperinsulinemia and was successfully treated with a long-acting somatostatin analogue, which had recently become available. The patient, a 72-year-old female, who had previously been diagnosed as insulinoma and undergone partial pancreatectomy, was admitted complaining of the recurrence of hypoglycemic attacks after an interval of ten years. On admission, hypoglycemia (42 mg/dl), hyperinsulinemia (IRI: 79.3 mU/m) and low HbA1c (3.6%) were present. In 75g-OGTT at 30 min after load, IRI reached 6623 mU/ml, while plasma glucose level was 88 mg/dl. The anti-insulin antibody was not present. Since attempts at tumor localization by imaging techniques failed and the patient refused further examinations or surgical treatment, we recommended her to take a medication with a somatostatin analogue. Insulin suppression test using 50 mg of octreotide improved plasma glucose and IRI levels, suggesting the usefulness of the treatment, and a monthly administration of 20 mg of long-acting octreotide has successfully controlled her symptoms of hypoglycemia for 10 months. Our case demonstrated the utility of the long-acting somatostatin analogue for long-term treatment of undetermined hyperinsulinemia. A preliminary loading test using short-acting octreotide may be useful to determine appropriate medication, especially in cases who cannot receive surgical treatment.
MAJOR causes of fasting hypoglycemia in adults are insulinoma, factitious hypoglycemia and nesidioblastosis [1] . Insulinoma is a relatively rare tumor of the pancreatic b-cells, which often causes severe and disabling hypoglycemia. It can occur at any age and has an equal sex distribution. As many as 90% of the insulinomas have been reported as benign, 90% solitary, and 75% less than 3 cm in size [2, 3] . Although surgical resection should be primarily selected as the treatment for insulinomas, there are cases that are not susceptible to major surgery because of failure in tumor localization, metastasis, aging, or severe obesity. Persistent hyperinsulinemic hypoglycemia (PHH) in adults that is not caused by an insulinoma is a rare and not well-characterized disease that has been named nesidioblastosis [1] . The somatostatin analogue, octreotide, has been successfully used in such cases of insulinomas and PHH. Octreotide is known to suppress secretion of various hormones from endocrine tissues or tumors including insulin secretion from the pancreatic b-cells via somatostatin receptor [4] .
We report here a case with recurrent severe hyperinsulinemia and moderate hypoglycemia, who underwent partial pancreatectomy under suspicion of insulinoma ten years ago. Since the patient refused to take further surgical treatment, we tried the somatostatin analogue therapy using long-acting octreotide (monthly dose of 20 mg), which has successfully controlled the patient's symptoms of hypoglycemia and metabolic parameters for the last 10 months.
Materials and Methods
Determination of immunoreactive insulin (IRI), Cpeptide (CPR) and serum insulin autoantibodies (IAA) 
Somatostatin analogue administration
Subcutaneous injections of minimal dose of octreotide (50 mg of Sandostatin, Novartis Pharma, Switzerland) were performed to assess the suppressing effect for insulin hypersecretion. In order to obtain long-term control of hyperinsulinemia, intra muscular injection of long-acting octreotide (Sandostatin LAR, Novartis Pharma, Switzerland) was performed monthly with a dose of 20 mg. Written informed consent was obtained from the patient. Results were expressed as mean ± SD and the differences between groups were analyzed by t-test. P value less than 0.05 was considered as statistically significant.
Case Report
A 72-year-old woman was admitted to our hospital complaining of frequent hypoglycemic attacks. She experienced the first symptom of hypoglycemia ten years ago at the age of 62, which led her to comatose state. Attempts at pancreatic tumor localization using abdominal ultrasonogram and abdominal CT scan failed. However, selective venous blood sampling test indicated hypersecretion of insulin from the tail part of pancreas, and exploratory surgery was performed for insulinoma in 1994. No definite tumor was identified during the operation, but partial pancreatectomy of the tail part was performed. Microscopic examination of the operated tissue revealed no tumorous cells or hyperplastic tissue, but there was an increased number of smaller islets. Insulin staining of pancreas sections revealed that these smaller islets had significant insulin-positive cells, but further characterization was unclear. After surgery, she became free of symptoms, which lasted thereafter.
In January 2004, however, she had a recurrence of hypoglycemic coma after an interval of ten years. The attacks occurred mainly in the morning and in fasting state, with more frequency than before. On admission to our hospital for further examination, her consciousness was alert, her body weight was 73.5 kg, height 151.4 cm, and body mass index 32.06. Blood pressure was 116/70 mmHg, pulse rate 72/min, regular, and body temperature 36.3°C. She had no symptoms of visual disturbance or neurological deficit.
Clinical course
Initial laboratory data at admission are summarized in Table 1 . Fasting plasma blood glucose level was 42 mg/dl, IRI was 79.3 mU/ml and HbA1c was 3.6%. Circadian variation test soon after the admission indicates that plasma glucose levels were low (40-85 mg/dl, during the day), especially in the morning (40 mg/dl), and IRI levels sharply rose from 15.1 to 1269 mU/ml after breakfast. She was shown to be DR4 positive by HLA serotype analysis, which is commonly detected in Japanese patients with insulin autoimmune syndrome. However, the binding percentage of [ 125 I] Insulin was 9.4%, thus excluding the possibility of the disorder. During hospitalization, IRI levels were measured several times when hypoglycemic coma occurred early in the morning, but fasting IRI levels were not so high as compared with those occasionally observed after meals. Upon 75g-oral glucose tolerance test (OGTT), extremely high IRI level was detected at 15 min after load and reached a maximum of 6623 mU/ml at 30 min (Fig. 1) . The plasma glucose level was 88 mg/dl at 30 min and showed a minimum value of 22 mg/dl at 120 min (Fig. 1) , when she developed syncope. Mean level of urinary C-peptide excretion was 83.5 mg/day, which seemed to be incompatible with her hyperinsulinemia.
Imaging studies including ultrasonogram, CT scan, MRI and MRCP (magnetic resonance cholangiopancreatography) aiming at tumor localization failed. Since the patient refused further examinations and any surgical treatment, we recommended a hormonesuppressing regimen using octreotide, a somatostatin analogue.
A subcutaneous octreotide injection of 50 mg before breakfast immediately suppressed IRI levels, and the suppression lasted for about 12 hr (Fig. 2, bold solid  line) . As the result, plasma glucose levels were elevated 4 hr after injection and the rise persisted for more than 8 hr (Fig. 2, thin solid line) . This result indicated that octreotide therapy was effective for prevention of hypoglycemic attacks, hence we started the octreotide therapy to control hyperinsulinemia. At first, 50 mg injection 2 hr after supper was started in order to avoid fasting hypoglycemia in the morning. On the first therapeutic day, marked improvements of both fasting plasma glucose level and post-breakfast IRI level, from 40 to 96 mg/dl and from 1269 to 308.2 mU/ml, respectively, were observed compared with those before treatment. Successive injection of 50 mg octreotide once a day increased the mean fasting plasma glucose level from 40.4 ± 3.0 mg/dl (n = 8) to 73.0 ± 9.0 mg/dl (n = 6, p<0.01). Subsequently, we changed the therapy from daily subcutaneous injection of octreotide to monthly intramuscular injection of long-acting octreotide (octreotide LAR). This therapy was also useful, and prevented her hypoglycemic attacks completely. Both postprandial plasma glucose (64.0 ± 6.0 mg/dl vs. 117.8 ± 8.7 mg/ dl, p<0.01) and postprandial IRI (139.5 ± 26.9 mU/ml vs. 51.0 ± 7.5 mU/ml, p<0.01) levels were improved, and HbA1c levels increased from 3.6 ± 0.9% to 4.8 ± 0.05% (p<0.05). Fig. 3 shows the time course of postprandial plasma glucose, IRI and HbA1c levels after 20 mg of octreotide LAR therapy. Marked improvements were observed in three parameters right after the treatment (Fig. 3) . During the follow-up period of 10 months, no adverse effects of this therapy were observed.
Discussion
We reported here a patient who showed undetermined hyperinsulinemia and was successfully treated for hypoglycemic attacks by the long-acting somatostatin analogue, octreotide LAR. There are several medications, such as diazoxide [5, 6] , dl-propranolol [7] , adriamycin or adriamycin + 5-flurouracil [8] , diphenylhydantoin [9] , phenytoin [10] , glucocorticoid, and octreotide [11] [12] [13] [14] [15] , which may be used to treat hypoglycemia in patients with hyperinsulinemia, including insulinoma or PHH. We tried daily administration of octreotide and obtained a satisfactory result. Fifty mg/day of octreotide effectively improved plasma glucose and IRI levels up to 8-12 hr after subcutaneous injection. By injections at 20:00 after supper, octreotide successfully improved fasting plasma glucose levels and IRI levels in the morning, which is the time period most susceptible to hypoglycemic attacks.
Since the long-acting somatostatin analogue, octreotide LAR, has recently become available, we subsequently selected the monthly administration therapy of this new drug to the patient, which was also satisfactorily effective without any adverse phenomena. The effectiveness of octreotide LAR treatment toward hyperinsulinemia has recently been reported in Western countries, but there are few detailed reports in Japan as of yet. This report will provide data on alternative treatment of insulinoma and PHH in Japanese cases using octreotide LAR. Octreotide is considered to act via the somatostatin receptors (SSTRs), among which, SSTR 2, 3 and/or 5 are specifically associated with the ligands including somatostatin, octreotide, and 111 In-pentetreotide, another somatostatin analogue labeled by the isotope, in terms of suppression of hormone secretion [16] . It is also speculated that SSTR 1, 2 and 5 are associated with suppression of cell growth [17] , and that activation of SSTR 2 and 3 induces cellular apoptosis in vitro [18] . Since octreotide was clearly effective in the present case, it is speculated that the SSTRs described above are expressed on the insulin-producing cells of our patient. This also suggests that somatostatin receptor scintigraphy (SSRS) might have been able to visualize the latent insulinoma in the patient, although 111 Inpentetreotide is not yet available in our country. A preliminary low-dose (50 mg) octreotide loading test may be useful not only to determine appropriate medication, but also to predict the performance of SSRS to localize the tumor in cases with latent insulinoma and PHH.
The leading cause of spontaneous hypoglycemia is fasting hyperinsulinemia induced by insulinomas, most of which are benign insulin-producing b-cell tumors in the pancreas [3, 19, 20] . Because of failure in tumor detection and lack of pathological confirmation, the final diagnosis of insulinoma could not be made in the present case. However, any of the criteria for diagnosis of insulinoma as proposed by Grunt, Fajans, Turner, Taminato or Tanaka indicated a positive sign: BS/ IRI = 0.53<2.5, IRI/BS = 1.9>0.5, IRI/(BS-30) × 100 = 658.3>260, (100-BS) × (IRI-3) = 4425.4>280 or CPR/ BS = 0.14>0.05, respectively [2] . Therefore a clinical diagnosis of insulinoma is strongly suspected. However, it is also possible that adult onset nesidioblastosis associated with PHH, which is very rare and represents 0.5-5.0% of cases of organic hyperinsulinemia [21] , can be a causal pathology of this patient. Surgical resection of the pancreas and careful histological analyses are necessary to arrive at a final diagnosis for this case.
Although we could not reach a final diagnosis, monthly administration of octreotide LAR treatment has been definitely effective to improve her hypo- glycemic symptoms as well as metabolic parameters such as glucose, IRI and HbA1c levels during the last 10 months. The dose of octreotide LAR is now 20 mg, and this should be considered during follow-up referring to these metabolic parameters.
There remain several questions to be addressed regarding the pathophysiology of the patient's hyperinsulinemia and hypoglycemia. The first one is that she presented with extremely high levels of serum IRI along with C-peptide than those in common cases of insulinoma. Peak IRI level reached more than 6600 mU/ml and hyperinsulinemia (IRI>1000 mU/ml) persisted until 120 min after 75-g glucose load (Fig. 1) . Extreme IRI elevations were also observed after breakfast. Secondly, although she had been under such severe hyperinsulinemia during OGTT, blood glucose did not fall under 50 mg/dl until 90 min after load, and a syncopal attack by delayed hypoglycemia developed at 120 min when IRI fell to 1160 mU/ml (Fig. 1) . Secondly, despite the high IRI levels urinary excretion of C-peptide was 83.5 mg/day, which was within normal range. Further study is necessary to understand the nature of this extraordinary case with undetermined hyperinsulinemia.
In conclusion, our case demonstrated the usefulness of the long-acting somatostatin analogue for the treatment of undetermined hyperinsulinemia. Octreotide loading test may be useful for predicting the determination of appropriate medication, especially in cases where attempts at tumor localization have failed.
